Mikiya ISHIHARA

Mie University Hospital

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Collaborators (4)

Yoshihiro Miyahara

Mie university

Minoru Miyashita

Tohoku University

Hiroshi Shiku

Yoshihiro Nishida

Nagoya University Hospital

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mikiya ISHIHARA

Research Interests

Explore related searches

Contact this professor

Articles (11)

Collaborators (4)

Yoshihiro Miyahara

Minoru Miyashita

Hiroshi Shiku

Yoshihiro Nishida

Make your next move.

Mikiya ISHIHARA

Research Interests

Explore related searches

Contact this professor

Articles (11)

αβ-T cell receptor transduction gives superior mitochondrial function to γδ-T cells with promising persistence

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

A phase 1 trial of NY‐ESO‐1‐specific TCR‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma

Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial

Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome

Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition (Breast Cancer, (2020), 27, 3, (322-331), 10.1007/s12282-020-01085-0)

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

A case of extragonadal germ cell tumor treated by induction therapy with a reduced bep regimen

CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression

Collaborators (4)

Yoshihiro Miyahara

Minoru Miyashita

Hiroshi Shiku

Yoshihiro Nishida

Make your next move.